Institut Pasteur Korea (IPK) and International Vaccine Institute (IVI) have signed a memorandum of understanding to cooperate on developing treatments and vaccines of infectious diseases. 

The two groups will reinvigorate research cooperation and information exchange to attain their common goal of promoting global public health. For this purpose, they will facilitate the exchanges and cooperation between the biomedical scientists and infectious disease experts at the two organizations and other related institutions by organizing joint workshops and seminars. 

The MOU will accelerate the development of treatments and vaccines by combining IPK’s research capabilities and technology with IVI’s vaccine development and clinical trial know-hows. The two are researching in various fields such as Covid-19, MERS, dengue fever and tuberculosis, according to IPK.

“IPK and IVI will be able to create synergy by utilizing each other’s strengths in research capabilities and global network,” IPK CEO Jee Young-mee said. “We will cooperate with IVI to promote public health and respond to act against global medical threats.”

IVI Director-General Jerome H. Kim also said, “We are pleased to work with IPK, an international research institute founded on scientific cooperation between Korea and France to co-develop vaccine and cure solutions for global threats. The partnership between the two will be able to break new ground for vaccine development.”